173 related articles for article (PubMed ID: 25276822)
1. Increased sialylation of anti-Thomsen-Friedenreich antigen (CD176) antibodies in patients with gastric cancer: a diagnostic and prognostic potential.
Kurtenkov O; Izotova J; Klaamas K; Sergeyev B
Biomed Res Int; 2014; 2014():830847. PubMed ID: 25276822
[TBL] [Abstract][Full Text] [Related]
2. Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients.
Kodar K; Izotova J; Klaamas K; Sergeyev B; Järvekülg L; Kurtenkov O
World J Gastroenterol; 2013 Jun; 19(23):3573-82. PubMed ID: 23801858
[TBL] [Abstract][Full Text] [Related]
3. Increased Avidity of the Sambucus nigra Lectin-Reactive Antibodies to the Thomsen-Friedenreich Antigen as a Potential Biomarker for Gastric Cancer.
Kurtenkov O; Klaamas K
Dis Markers; 2015; 2015():761908. PubMed ID: 26663951
[TBL] [Abstract][Full Text] [Related]
4. Signatures of anti-Thomsen - Friedenreich antigen antibody diversity in colon cancer patients.
Kurtenkov O; Bubina M; Klaamas K
Exp Oncol; 2018 Mar; 40(1):48-58. PubMed ID: 29600973
[TBL] [Abstract][Full Text] [Related]
5. Hidden IgG Antibodies to the Tumor-Associated Thomsen-Friedenreich Antigen in Gastric Cancer Patients: Lectin Reactivity, Avidity, and Clinical Relevance.
Kurtenkov O; Klaamas K
Biomed Res Int; 2017; 2017():6097647. PubMed ID: 28316982
[TBL] [Abstract][Full Text] [Related]
6. The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer.
Kurtenkov O; Innos K; Sergejev B; Klaamas K
Biomed Res Int; 2018; 2018():9579828. PubMed ID: 30105268
[TBL] [Abstract][Full Text] [Related]
7. Postoperative change of anti-Thomsen-Friedenreich and Tn IgG level: the follow-up study of gastrointestinal cancer patients.
Smorodin EP; Kurtenkov OA; Sergeyev BL; Kodar KE; Chuzmarov VI; Afanasyev VP
World J Gastroenterol; 2008 Jul; 14(27):4352-8. PubMed ID: 18666325
[TBL] [Abstract][Full Text] [Related]
8. The Thomsen-Friedenreich antigen and alphaGal-specific human IgG glycoforms: concanavalin A reactivity and relation to survival of cancer patients.
Kodar K; Kurtenkov O; Klaamas K
Immunol Invest; 2009; 38(8):704-17. PubMed ID: 19860583
[TBL] [Abstract][Full Text] [Related]
9. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival.
Kurtenkov O; Klaamas K; Mensdorff-Pouilly S; Miljukhina L; Shljapnikova L; Chuzmarov V
Acta Oncol; 2007; 46(3):316-23. PubMed ID: 17450466
[TBL] [Abstract][Full Text] [Related]
10. Cluster binding studies with two anti-Thomsen-Friedenreich (anti-core-1, CD176, TF) antibodies: Evidence for a multiple TF epitope.
Flechner A; Butschak G; Löffler A; Rühmann J; Nishimura SI; Dölling R; Purfürst B; Goletz S; Danielczyk A; Karsten U
Int Immunopharmacol; 2019 Jul; 72():186-194. PubMed ID: 30999209
[TBL] [Abstract][Full Text] [Related]
11. The relation of the level of serum anti-TF, -Tn and -alpha-Gal IgG to survival in gastrointestinal cancer patients.
Smorodin E; Sergeyev B; Klaamas K; Chuzmarov V; Kurtenkov O
Int J Med Sci; 2013; 10(12):1674-82. PubMed ID: 24151439
[TBL] [Abstract][Full Text] [Related]
12. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation.
Käsermann F; Boerema DJ; Rüegsegger M; Hofmann A; Wymann S; Zuercher AW; Miescher S
PLoS One; 2012; 7(6):e37243. PubMed ID: 22675478
[TBL] [Abstract][Full Text] [Related]
13. [ELISA of IgM antibodies to Thomsen-Friedenreich (TF) hapten in cancer diagnostics: comparison of data obtained with four TF-glycoconjugates].
Smorodin EP; Jansson B; Miliukhina L; Paaski G; Bovin NV; Ovchinnikova TV; Kurtenkov O
Bioorg Khim; 1997 Oct; 23(10):795-9. PubMed ID: 9490614
[TBL] [Abstract][Full Text] [Related]
14. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen.
MacLean GD; Bowen-Yacyshyn MB; Samuel J; Meikle A; Stuart G; Nation J; Poppema S; Jerry M; Koganty R; Wong T
J Immunother (1991); 1992 May; 11(4):292-305. PubMed ID: 1599915
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer.
Heublein S; Egger M; Zhu J; Berger L; Mayr D; Schindlbeck C; Kuhn C; Hofmann SS; Schuetz F; Jeschke U; Ditsch N
Breast Cancer Res Treat; 2020 Feb; 179(3):643-652. PubMed ID: 31828591
[TBL] [Abstract][Full Text] [Related]
16. Thomsen-Friedenreich glycotope is expressed in developing and normal kidney but not in renal neoplasms.
Toma V; Zuber C; Sata T; Komminoth P; Hailemariam S; Eble JN; Heitz PU; Roth J
Hum Pathol; 2000 Jun; 31(6):647-55. PubMed ID: 10872656
[TBL] [Abstract][Full Text] [Related]
17. Immunoreactivity of monoclonal antibody BW835 represents a marker of progression and prognosis in early gastric cancer.
Baldus SE; Zirbes TK; Glossmann J; Fromm S; Hanisch FG; Mönig SP; Schröder W; Schneider PM; Flucke U; Karsten U; Thiele J; Hölscher AH; Dienes HP
Oncology; 2001; 61(2):147-55. PubMed ID: 11528254
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Immune Response Against the Thomsen-Friedenreich Tumor Antigen Using a Bivalent Entirely Carbohydrate Conjugate.
Kleski KA; Trabbic KR; Shi M; Bourgault JP; Andreana PR
Molecules; 2020 Mar; 25(6):. PubMed ID: 32183149
[TBL] [Abstract][Full Text] [Related]
19. [Expression of galectin 3 and Sambucus nigra agglutinin and their clinicopathological significance in benign and malignant lesions of stomach].
Zhou JP; Yang ZL; Liu DC; Zhou JP
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 May; 12(3):297-300. PubMed ID: 19434543
[TBL] [Abstract][Full Text] [Related]
20. Natural IgM and IgG antibodies to Thomsen-Friedenreich (T) antigen in serum of patients with gastric cancer and blood donors--relation to Lewis (a,b) histo-blood group phenotype.
Kurtenkov O; Miljukhina L; Smorodin J; Klaamas K; Bovin N; Ellamaa M; Chuzmarov V
Acta Oncol; 1999; 38(7):939-43. PubMed ID: 10606423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
